NGEN
NervGen Pharma Corp. Common stock NASDAQ Listed Feb 8, 2021$1.76
Pre-mkt
$1.78
+1.14%
Mkt Cap $144.7M
52w Low $1.58
3.8% of range
52w High $6.30
50d MA $1.93
200d MA $3.23
P/E (TTM)
—
EV/EBITDA
—
P/B
36.6x
Debt/Equity
0.0x
ROE
—
P/FCF
-6.5x
RSI (14)
29.90
ATR (14)
$0.13
Beta
0.99
50d MA
$1.93
200d MA
$3.23
Avg Volume
601.4K
NervGen Pharma Corp. is a clinical-stage biotechnology company developing therapies aimed at treating nerve damage and neurodegenerative conditions by targeting mechanisms that inhibit nervous system repair.
1455 Bellevue Avenue, Suite 301 · West Vancouver, BC V7T 1C3 · CA
Data updated apr 26, 2026 2:55pm
· Source: financialmodelingprep.com